Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
- 17 April 2023
- journal article
- review article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (7) , 694-713
Abstract
The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01CA175495, R01CA262132)
- U.S. Department of Health & Human Services | National Institutes of Health
This publication has 251 references indexed in Scilit:
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2Journal of Experimental Medicine, 2012
- Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesisMolecular Biology of the Cell, 2012
- Regulation and function of mTOR signalling in T cell fate decisionsNature Reviews Immunology, 2012
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJournal of Translational Medicine, 2011
- PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8+ T cellsEMBO Molecular Medicine, 2011
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaJournal of Neuro-Oncology, 2009
- Determination of glycosylation sites and site-specific heterogeneity in glycoproteinsCurrent Opinion in Chemical Biology, 2009
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signalNature Immunology, 2009
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Tissue expression of PD-L1 mediates peripheral T cell toleranceJournal of Experimental Medicine, 2006